Drugmakers are constantly reviewing their businesses. Over the past several years, those reviews have led to asset swaps and slim-downs, with companies selling or spinning businesses that weren't getting the job done. Lately, though? They've resulted in full-scale rebrands for some pharmas—more often than not, yielding a new focus on oncology, rare diseases or both.
